Abstract
Dysregulated leukocyte recruitment is believed to be a key contributor to various acute and chronic inflammatory disorders which can lead to serious pathological consequences. Chemokines are small molecular weight proteins that have been shown to be imperative in the direction of leukocytes to the sites of inflammation. In humans, several of these chemokines (CXCL8 and CXCL1) are elevated in inflammatory disorders such as asthma, arthritis, and chronic obstructive pulmonary disease (COPD). These chemokines modulate their downstream effects thru G-protein coupled receptors, such as CXCR2, making the identification of small-molecule antagonists of this receptor attractive towards developing novel therapies to treat inflammatory conditions. Since the first report of a CXCR2 receptor antagonist in 1998, there has been a considerable effort conducted mainly in the pharmaceutical industry to identify novel classes of CXCR2 receptor antagonists. Over a dozen distinct classes of CXCR2 receptor antagonists have been reported in the literature to date with a number of these compounds having reached mid-stage clinical trials. This review will provide a broad overview the medicinal chemistry efforts over the past 15 years towards the identification of CXCR2 receptor antagonists. The discussion will focus upon the early preclinical space covering the structure activity relationships (SAR), pharmacology, as well in preclinical in vivo evaluation for the different series of CXCR2 receptor antagonists. In addition, the available clinical data for the most advanced compounds in the clinic will be discussed and along with a perspective of the area moving forward.
Keywords: Chemokine, COPD, CXCR2, CXCR2 receptor antagonist, Gro-α (CXCL1), Interleukin-8 (IL-8 or CXCL8), medicinal chemistry.
Current Topics in Medicinal Chemistry
Title:CXCR2 Receptor Antagonists: A Medicinal Chemistry Perspective
Volume: 14 Issue: 13
Author(s): Michael P. Dwyer and Younong Yu
Affiliation:
Keywords: Chemokine, COPD, CXCR2, CXCR2 receptor antagonist, Gro-α (CXCL1), Interleukin-8 (IL-8 or CXCL8), medicinal chemistry.
Abstract: Dysregulated leukocyte recruitment is believed to be a key contributor to various acute and chronic inflammatory disorders which can lead to serious pathological consequences. Chemokines are small molecular weight proteins that have been shown to be imperative in the direction of leukocytes to the sites of inflammation. In humans, several of these chemokines (CXCL8 and CXCL1) are elevated in inflammatory disorders such as asthma, arthritis, and chronic obstructive pulmonary disease (COPD). These chemokines modulate their downstream effects thru G-protein coupled receptors, such as CXCR2, making the identification of small-molecule antagonists of this receptor attractive towards developing novel therapies to treat inflammatory conditions. Since the first report of a CXCR2 receptor antagonist in 1998, there has been a considerable effort conducted mainly in the pharmaceutical industry to identify novel classes of CXCR2 receptor antagonists. Over a dozen distinct classes of CXCR2 receptor antagonists have been reported in the literature to date with a number of these compounds having reached mid-stage clinical trials. This review will provide a broad overview the medicinal chemistry efforts over the past 15 years towards the identification of CXCR2 receptor antagonists. The discussion will focus upon the early preclinical space covering the structure activity relationships (SAR), pharmacology, as well in preclinical in vivo evaluation for the different series of CXCR2 receptor antagonists. In addition, the available clinical data for the most advanced compounds in the clinic will be discussed and along with a perspective of the area moving forward.
Export Options
About this article
Cite this article as:
Dwyer P. Michael and Yu Younong, CXCR2 Receptor Antagonists: A Medicinal Chemistry Perspective, Current Topics in Medicinal Chemistry 2014; 14 (13) . https://dx.doi.org/10.2174/1568026614666140827144615
DOI https://dx.doi.org/10.2174/1568026614666140827144615 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Interventions to Attenuate Alzheimer’s Disease Progression: The Story So Far
Current Alzheimer Research Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Guide of Hypertensive Crisis Pharmacotherapy
Cardiovascular & Hematological Disorders-Drug Targets Glucocorticoid Excess Induces Accumulation of Cardiac Glycogen and Triglyceride: Suggested Role for AMPK
Current Pharmaceutical Design Electrochemical Immunosensors for Disease Detection and Diagnosis
Current Medicinal Chemistry <i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal Perception or Reality of Body Weight: Which Matters the Most to Adolescents’ Emotional Well-being?
Current Psychiatry Reviews COX-2 Inhibitors Celecoxib and Parecoxib: Valuable Options for Postoperative Pain Management
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Toxicities by Herbal Medicines with Emphasis to Traditional Chinese Medicine
Current Drug Metabolism Complementary and Alternative Medicine for Childhood Asthma: An Overview of Evidence and Patents
Recent Patents on Inflammation & Allergy Drug Discovery CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Nanoparticle as An Emerging Tool in Pulmonary Drug Delivery System
Micro and Nanosystems Common Issues Among Asthma, Epilepsy, and Schizophrenia: From Inflammation to Ca<sup>2+</sup>/cAMP Signalling
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Drug Repositioning: A Smart Approach for Combating SARS-CoV-2
Anti-Infective Agents Medication Conveyance Through Nose: Factors Affecting and Novel Applications
Drug Delivery Letters Generation of the Fluorescent HMGB1-GFP Fusion Protein in Insect Cells and Evaluation of its Immunogenicity in Two Mice Models
Protein & Peptide Letters Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies Peptide-Based Allergen Specific Immunotherapy for the Treatment of Allergic Disorders
Recent Patents on Inflammation & Allergy Drug Discovery